Short-term outcomes of robot-assisted versus conventional minimally invasive esophagectomy for esophageal cancer: a systematic review and meta-analysis of 18,187 patients
Journal of Robotic Surgery · 2024
DOI: 10.1007/s11701-024-01880-3 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Robotic Surgery, 2024. Verfasst von Rui Perry und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Porto, Porto, Portugal. rui-perry@sapo.pt. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Esophagectomy, Minimally Invasive Surgical Procedures, Postoperative Complications. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidade do Porto.
Abstract (Originalsprache)
The role of robotic surgery in the curative-intent treatment of esophageal cancer patients is yet to be defined. To compare short-term outcomes between conventional minimally invasive (cMIE) and robot-assisted minimally invasive esophagectomy (RAMIE) in esophageal cancer patients. PubMed, Web of Science and Cochrane Library were systematically searched. The included studies compared short-term outcomes between cMIE and RAMIE. Individual risk of bias was calculated using the MINORS and RoB2 scales. There were no statistically significant differences between RAMIE and cMIE regarding conversion to open procedure, mean number of harvested lymph nodes in the mediastinum, abdomen and along the right recurrent laryngeal nerve (RLN), 30- and 90-day mortality rates, chyle leakage, RLN palsy as well as cardiac and infectious complication rates. Estimated blood loss (MD − 71.78 mL, p < 0.00001), total number of harvested lymph nodes (MD 2.18 nodes, p < 0.0001) and along the left RLN (MD 0.73 nodes, p = 0.03), pulmonary complications (RR 0.70, p = 0.001) and length of hospital stay (MD − 3.03 days, p < 0.0001) are outcomes that favored RAMIE. A significantly shorter operating time (MD 29.01 min, p = 0.004) and a lower rate of anastomotic leakage (RR 1.23, p = 0.0005) were seen in cMIE. RAMIE has indicated to be a safe and feasible alternative to cMIE, with a tendency towards superiority in blood loss, lymph node yield, pulmonary complications and length of hospital stay. There was significant heterogeneity among studies for some of the outcomes measured. Further studies are necessary to confirm these results and overcome current limitations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, University of Porto, Porto, Portugal. rui-perry@sapo.pt.
- Faculty of Medicine, University of Porto, Porto, Portugal.
- Department of Community Medicine, Information and Decision in Health, Faculty of Medicine, University of Porto, Porto, Portugal.
- Department of Stomatology, São João University Hospital Center, Porto, Portugal.
- Faculty of Medicine, University of Salamanca, Salamanca, Spain.
- Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal.
Förderung
- Universidade do Porto
Zitieren
APA
Perry, R., Barbosa, J. P., Perry, I., & Barbosa, J. (2024). Short-term outcomes of robot-assisted versus conventional minimally invasive esophagectomy for esophageal cancer: a systematic review and meta-analysis of 18,187 patients. Journal of Robotic Surgery. https://doi.org/10.1007/s11701-024-01880-3
Vancouver
Perry R, Barbosa JP, Perry I, Barbosa J. Short-term outcomes of robot-assisted versus conventional minimally invasive esophagectomy for esophageal cancer: a systematic review and meta-analysis of 18,187 patients. Journal of Robotic Surgery. 2024. doi:10.1007/s11701-024-01880-3
BibTeX
@article{Perry2024,
author = {Perry, Rui and Barbosa, José Pedro and Perry, Isabel and Barbosa, José},
title = {Short-term outcomes of robot-assisted versus conventional minimally invasive esophagectomy for esophageal cancer: a systematic review and meta-analysis of 18,187 patients},
journal = {Journal of Robotic Surgery},
year = {2024},
doi = {10.1007/s11701-024-01880-3}
}
EUVIMED